secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001171843-21-007565
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q3 revenue up 25% to $39.5M, net income $0.6M; cuts FY2021 revenue growth outlook to 9-11% from 11-14%
--------------------------------------------------------------------------------

- Revenue $39.5M (+25% YoY); Joint Pain Management up 42% to $26.2M.
- Net income $0.6M ($0.04 diluted) vs net loss $6.4M a year ago; adjusted net income $0.8M ($0.05 diluted).
- Adjusted EBITDA $5.8M vs $4.9M; operating cash flow $2.1M; cash $91.0M.
- FY2021 revenue growth guidance revised to 9-11% (previously 11-14%) due to COVID Delta variant headwinds.
- Launched WristMotion Total Wrist Arthroplasty; received 510(k) clearance for Tactoset hardware augmentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184321007565/0001171843-21-007565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184321007565/f8k_110421.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-007565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer